WHO clears first malaria drug designed for babies

The world just crossed a long-delayed line in the fight against malaria: babies now have a treatment designed for them.

The World Health Organization has prequalified Coartem Baby, clearing the first malaria drug specifically approved for newborns and very young infants. That decision matters because clinicians have long faced a dangerous gap. In places where malaria hits hardest, reports indicate many children under six months still become infected, yet health workers have lacked a medicine proven safe for the smallest bodies. Instead, care often relied on treatments intended for older children, a workaround that exposed a profound failure in pediatric medicine.

The scale of the need gives the approval its urgency. Malaria killed 610,000 people in 2024, according to the news signal, and about three quarters of those deaths fell on under-fives in Africa. Even without a full breakdown for the youngest infants, the numbers point to a brutal truth: the burden lands heaviest on children, and the earliest months of life have remained especially exposed. A drug tailored to babies will not erase that toll on its own, but it removes one glaring blind spot in treatment.

This is more than a technical approval; it closes a deadly gap that left the youngest malaria patients without a medicine made for them.

The breakthrough also highlights a broader shift in global health priorities. For years, newborns and very young infants often sat at the edge of drug development, especially for diseases concentrated in lower-income countries. WHO prequalification does not just signal safety and quality. It also creates a pathway for procurement and wider distribution, giving governments and health programs a chance to move from improvised care to age-appropriate treatment. Sources suggest that shift could strengthen confidence among frontline providers who have had few good options.

What happens next will determine whether this moment becomes a milestone on paper or a real change in survival. Countries, manufacturers, donors, and health systems now need to translate approval into supply, access, and routine use where malaria strikes early and often. If that chain holds, the decision could save lives far beyond a regulatory headline — and prove that even long-neglected patients do not have to remain invisible.